Sutkowski, D M <br/><br/>
Responses of LNCaP prostatic adenocarcinoma cell cultures to LY300502, a benzoquinolinone human type I 5alpha-reductase inhibitor.  [electronic resource] 

 -  The Prostate. Supplement  1996 
 - 62-6 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1050-5881 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Cell Division--drug effects<br/>Cholestenone 5 alpha-Reductase<br/>Dihydrotestosterone--metabolism<br/>Enzyme Inhibitors--pharmacology<br/>Humans<br/>Male<br/>Oxidoreductases--antagonists & inhibitors<br/>Prostate-Specific Antigen--metabolism<br/>Prostatic Neoplasms--drug therapy<br/>Quinolones--pharmacology<br/>Tumor Cells, Cultured